Fishman Pnina 4

What Happened

• Pnina Fishman, Chief Scientific Officer and a director of Can‑Fite BioPharma Ltd. (CANF), was granted 24,000 derivative awards on 2026-06-04. The grant is reported as an acquisition (award) with $0 cash paid at grant because these are stock options (derivative instruments). The exercise price is NIS 5.94, presented in the filing as approximately $2.04 per share based on the Bank of Israel exchange rate on June 5, 2026. If fully exercised, the aggregate exercise cost would be roughly $49,000.

Key Details

• Transaction date: 2026-06-04; Form 4 filed 2026-06-08.
• Award: 24,000 options (reported as "Acquired" at $0.00 since this is an option grant / derivative).
• Exercise price: NIS 5.94 ≈ USD 2.04 (Bank of Israel rate 2.908 NIS = 1 USD on 2026-06-05).
• Vesting: 16 equal quarterly installments beginning 09/04/2026 and ending 04/06/2030, subject to continued service.
• Trustee/tax note: Options must be registered in the name of a trustee to qualify for certain Israeli tax benefits (per filing footnote).
• Shares/options owned after the transaction: not specified in the provided filing.

Context

• This was an option grant (award), not a cash purchase or sale — a common form of executive compensation. It does not represent immediate buying or selling of open‑market shares; value to the holder depends on future vesting and whether the market price exceeds the exercise price.
• No indication in the filing about immediate sale (cashless exercise) or other disposition. The filing simply documents the grant and its vesting/exercise terms.